Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Non-Current Debt (2021 - 2023)

Pulse Biosciences has reported Non-Current Debt over the past 3 years, most recently at $65.0 million for Q1 2023.

  • Quarterly results put Non-Current Debt at $65.0 million for Q1 2023, changed N/A from a year ago — trailing twelve months through Mar 2023 was $65.0 million (changed N/A YoY), and the annual figure for FY2022 was $65.0 million, changed.
  • Non-Current Debt for Q1 2023 was $65.0 million at Pulse Biosciences, roughly flat from $65.0 million in the prior quarter.
  • Over the last five years, Non-Current Debt for PLSE hit a ceiling of $65.0 million in Q3 2022 and a floor of $41.0 million in Q1 2021.
  • Median Non-Current Debt over the past 3 years was $65.0 million (2022), compared with a mean of $59.0 million.